Shanghai Pharmaceuticals Holding Co Ltd

Shanghai Pharmaceuticals Holding Co Ltd maintains a debt-to-equity ratio of 0.76, indicating a moderate level of leverage. The company's liquidity position is characterized as medium, with a current ratio of 1.33, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. Free cash flow for the period was 4.69 billion CNY, while capital expenditures were -2.33 billion CNY, indicating a net outflow from investment in fixed assets. In terms of profitability, the company's return on equity (ROE) is 7.54%, and its return on assets (ROA) is 2.46%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming its peers in terms of generating returns from equity and total assets. The operating margin, calculated as operating income divided by revenue, is 3.49%, which is also below the industry median, indicating that the company is less efficient in converting revenue into operating profit. The company's revenue is primarily concentrated in China, with no significant international exposure disclosed in the available data. The company operates in a single business segment, which is pharmaceuticals and medical research. This lack of diversification increases the company's exposure to domestic economic and regulatory risks. Looking ahead, the company's revenue is expected to grow, with a positive outlook for the current fiscal year. However, the exact growth rate is not specified in the available data. The company's capital expenditures are expected to remain negative, indicating continued investment in fixed assets. The company's net income is expected to increase, driven by higher revenue and improved cost management. The company faces several risk factors, including liquidity risk due to its medium liquidity position and the fact that its net cash is negative after subtracting total debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the available data. The company's risk assessment also highlights the importance of monitoring its debt levels and liquidity position to ensure financial stability. Recent events, including analyst estimates and recommendations, suggest a generally positive outlook for the company. The mean price target is 13.46 CNY, with a median price target of 14.00 CNY. The mean recommendation is 2.12, indicating a slight bias towards a buy rating. However, the company has not disclosed any recent filings or transcripts that would provide additional insight into its operations or strategic direction.